Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

J Schuster, Stephen; R Bishop, Michael; S Tam, Constantine; K Waller, Edmund; Borchmann, Peter; P McGuirk, Joseph; Jäger, Ulrich; Jaglowski, Samantha; Andreadis, Charalambos; R Westin, Jason; Fleury, Isabelle; Bachanova, Veronika; Ronan Foley, S; Joy Ho, P; Mielke, Stephan; M Magenau, John; Holte, Harald; Pantano, Serafino; B Pacaud, Lida; Awasthi, Rakesh; Chu, Jufen; Anak, Özlem; Salles, Gilles; T Maziarz, Richard; Investigators, JULIET

doi:10.1056/NEJMoa1804980

Public

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Shared by NobleBlocks on Jan 3, 2019 • 12:00 AM UTC

Authors:

Stephen J Schuster

Michael R Bishop

Constantine S Tam

Abstract

BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cel...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!